Recent Updates
Recently added Catalysts

Temferon

Phase 1

Glioblastoma Multiforme | Small molecule | Oncology |Genenta Science S.p.A.|Last Updated: Jun 11, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment27

FDA Designations

No designations recorded
Trial Stopped -NCT03866109: LVLP (pt GBM-01034) took place on 27may2026. The 2 remaining slots allocated by the protocol for the additional cohort to generate safety data prior to study Part B will not be filled. No safety concerns. Benefit-risk profile unchanged.

Clinical trial landscape

Temferon · 1 trial · 1 indication

Phase 1 1
NCT03866109A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMTGlioblastoma Multiforme
TERMINATED25 Analytics
PHASE1TERMINATED
A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
Glioblastoma Multiforme
NCT0386610925
Unlock trial analytics

Study Endpoints

Primary Endpoints

Tolerability and safety of Temferon over the first 90 days following administration as determined by the incidence of adverse events
90 days

Routine clinical and laboratory surveillance

Secondary Endpoints

Long term tolerability and safety of Temferon as determined by the incidence of adverse events
2 years
Proportion of patients achieving haematologic recovery by Day +30 (defined as the first of at least 3 consecutive days with a neutrophil count >0.5 x 10^9/L and platelet count >20 x 10^9/L)
30 days
Determine the maximum tolerated dose of Temferon
30 days
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
TemferonEXPERIMENTALAutologous CD34+-enriched hematopoietic progenitor cells exposed in vitro to specific lentiviral vector encoding for the human interferon-alpha 2 gene. Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of interferon-alpha2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny.

Interventions

NameTypeDescription
TemferonDRUGGenetically modified HSPCs
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 70 Years
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: * Histologically confirmed, newly diagnosed supratentorial glioblastoma with unmethylated MGMT gene promoter. * Patients have undergone complete or partial tumor resection. * Able and willing to provide written informed consent and comply with the study protocol and procedures. ...

Countries:Italy
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMJul 12, 2026NCT03866109TRIAL_REMOVED: changed
MEDIUMJul 12, 2026NCT03866109TRIAL_REMOVED: changed
MEDIUMJul 12, 2026NCT03866109TRIAL_REMOVED: changed
MEDIUMJul 12, 2026NCT03866109TRIAL_REMOVED: changed
CRITICALJun 11, 2026NCT03866109Status: ACTIVE_NOT_RECRUITING → TERMINATED
CRITICALJun 11, 2026NCT03866109Status: ACTIVE_NOT_RECRUITING → TERMINATED
MEDIUMJun 7, 2026NCT03866109Phase: PHASE1/PHASE2 → PHASE1
MEDIUMJun 7, 2026NCT03866109Phase: PHASE1/PHASE2 → PHASE1
MEDIUMJun 7, 2026NCT03866109Phase: PHASE1/PHASE2 → PHASE1
MEDIUMJun 7, 2026NCT03866109Phase: PHASE1/PHASE2 → PHASE1
MEDIUMJun 7, 2026NCT03866109Phase: PHASE1/PHASE2 → PHASE1
MEDIUMJun 7, 2026NCT03866109Phase: PHASE1/PHASE2 → PHASE1

Frequently asked questions about Temferon

What is Temferon used for?

Temferon is an investigational therapy being studied for the treatment of Glioblastoma Multiforme, a type of brain cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.

Who is developing Temferon?

Temferon is being developed by Genenta Science S.p.A., a biopharmaceutical company. The company's stock is listed under the ticker symbol GNTA.

What phase is Temferon in?

Temferon is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use and is still being evaluated in clinical trials.

What clinical trials is Temferon in?

Temferon is being evaluated in a Phase 1 clinical trial with the identifier NCT03866109. This trial is studying Temferon in patients with Glioblastoma and unmethylated MGMT. The trial was terminated and enrolled 25 participants in Italy.

Is Temferon a small molecule?

Yes, Temferon is classified as a small molecule. It is being studied as a potential treatment for Glioblastoma Multiforme, an aggressive form of brain cancer.